Donor pretreatment with progenipoietin-1 is superior to granulocyte colony–stimulating factor in preventing graft-versus-host disease after allogeneic stem cell …

KPA MacDonald, V Rowe, C Filippich… - Blood, The Journal …, 2003 - ashpublications.org
KPA MacDonald, V Rowe, C Filippich, R Thomas, AD Clouston, JK Welply, DNJ Hart…
Blood, The Journal of the American Society of Hematology, 2003ashpublications.org
The granulocyte colony-stimulating factor (G-CSF) and Flt-3 receptor agonist progenipoietin-
1 (ProGP-1) has potent effects on dendritic cell (DC) expansion and may be an alternative to
G-CSF for the mobilization of stem cells for allogeneic stem cell transplantation (SCT). We
studied the ability of stem cell grafts mobilized with this agent to induce graft-versus-host
disease (GVHD) to minor and major histocompatibility antigens in the well-described B6→
B6D2F1 SCT model. ProGP-1, G-CSF, or control diluent was administered to donor B6 mice …
The granulocyte colony-stimulating factor (G-CSF) and Flt-3 receptor agonist progenipoietin-1 (ProGP-1) has potent effects on dendritic cell (DC) expansion and may be an alternative to G-CSF for the mobilization of stem cells for allogeneic stem cell transplantation (SCT). We studied the ability of stem cell grafts mobilized with this agent to induce graft-versus-host disease (GVHD) to minor and major histocompatibility antigens in the well-described B6 → B6D2F1 SCT model. ProGP-1, G-CSF, or control diluent was administered to donor B6 mice. ProGP-1 expanded all cell lineages in the spleen, and unseparated splenocytes from these animals produced large amounts of interleukin 10 (IL-10) and transforming growth factor beta (TGFβ) whereas the expression of T-cell adhesion molecules was diminished. Transplantation survival was 0%, 50%, and 90% in recipients of control-, G-CSF–, and ProGP-1–treated allogeneic donor splenocytes, respectively (P < .0001). Donor pretreatment with ProGP-1 allowed a 4-fold escalation in T-cell dose over that possible with G-CSF. Donor CD4 T cells from allogeneic SCT recipients of ProGP-1 splenocytes demonstrated an anergic response to host antigen, and cytokine production (interferon gamma [IFNγ], IL-4, and IL-10) was also reduced while CD8 T-cell cytotoxicity to host antigens remained intact. Neither CD11chi DCs nor CD11cdim/B220hi DCs from ProGP-1–treated animals conferred protection from GVHD when added to control spleen. Conversely, when equal numbers of purified T cells from control-, G-CSF–, or ProGP-1–treated allogeneic donors were added to allogeneic T-cell–depleted control spleen, survival at day 60 was 0%, 15%, and 90%, respectively (P < .0001). The improved survival in recipients of ProGP-1 T cells was associated with reductions in systemic tumor necrosis factor alpha generation and GVHD of the gastrointestinal tract. We conclude that donor pretreatment with ProGP-1 is superior to G-CSF for the prevention of GVHD after allogeneic SCT, primarily due to incremental affects on T-cell phenotype and function.
ashpublications.org